Abstract
The potential antitumoural effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) led us to evaluate GM-CSF alone or with dacarbazine (DTIC) in metastatic melanoma in first line randomized phase II. Treatment was arm A: GM-CSF: 5 μg kg–1, bid, 14 consecutive days every 21 days and arm B: GM-CSF: 5 μg kg–1, bid, day 2 to day 19 every 21 days and DTIC: 800 mg m–2, day 1 of each cycle. 32 patients (pts) were included, 15 pts in arm A and 17 in arm B. All pts had visceral metastatic sites. 9 had only one metastatic site. The median number of cycles given was 2 in arm A and 3 in arm B. 100% and 89.4% of the planned dose of GM-CSF was given in arm A and arm B respectively. No objective response was obtained. 19 pts experienced at least WHO grade 3 toxicity. All pts had fever, 29 had a decrease in performance status and 23 had pain. Grade 3 toxicity were fever (38.7%), decrease in performance status (32.3%), pain (19.4%) and dyspnoea (12.5%). In this study, GM-CSF alone or in association with DTIC did not induce any antitumoural activity with subsequent toxicity. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Armitage JO (1998) Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 92: 4491–4508
Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L and Rosenberg SA (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17: 2105–2116
Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peters L and Kian Ang K (1997) Cutaneous melanoma. In: Cancer principles and practice in oncology, 5th edition De Vita VT, Hellman S, Rosenberg SA (eds) pp 1947–1994. Philadelphia: Lippincott
Bender A, Sapp M, Schuler G, Steinman RM and Bhardwaj N (1996) Improved methods for the generation of dendritic cells from non proliferating progenitors in human blood. Immunol Methods 196: 121–131
Coulon V, Ravaud A, Gaston R, Delaunay M, Pariente JL, Verdier D, Scrivante V and Gualde N (2000) In vitro immunization of patient T cells with autologous bone marrow antigen presenting cells pulsed with tumour lysates. Int J Cancer 88: 783–790
Demirer T, Buckner CD and Bensinger WI (1996) Optimization of peripheral blood stem cell mobilization. Stem Cells 14: 106–116
Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S and Cheever MA (1996) Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88: 202–210
Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D and Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific and long lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539–3543
Edmonson JH, Long HJ and Kvols LK (1994) Cytotoxic drugs plus subcutaneous granulocyte-macrophage colony-stimulating factor: can molgrastim enhance antisarcoma therapy?. J Natl Cancer Inst 86: 312–314
Edmonson JH, Long HJ, Kvols LK, Mann BS and Grill JP (1997) Can molgrastim enhance the antitumour effect of cytotoxic drugs in patients with advanced sarcoma?. Ann Oncol 8: 637–641
Gehan EA (1961) The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeut agent. J Chron Dis 13: 346–353
Grabstein KH, Urdal DL, Tushinski RJ, Mochizuki DY, Price VL, Cantrell MA, Gillis S and Conlon PJ (1986) Induction of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor. Science 232: 506–508
Greenberg P, Advani R, Keating A, Gulati SC, Nimer S, Champlin R, Karanes C, Gorin NC, Powles RL, Smith A, Lamborn K and Cuffie C (1996) GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 18: 1057–1064
Hill AD, Redmond HP, Austin OM, Grace PA and Bouchier-Hayes D (1993) Granulocyte-macrophage colony-stimulating factor inhibits tumor growth. Br J Surg 80: 1543–1546
Ho RC (1995) Medical management of stage IV malignant melanoma. Cancer 75, (Suppl 2):735–741
Jäger E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jager D, Ilsemann C, Hagedorn M, Oesch F and Knuth A (1996) Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67: 54–62
Kaplan G, Walsh G, Guido LS, Meyn P, Burkhardt RA, Abalos RM, Barker J, Frindt PA, Fajardo TT and Celona R et al (1992) Novel response of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med 175: 1717–1728
Kass E, Panicali DL, Mazzara G, Schlom J and Greiner JW (2001) Granulocyte/ macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 61: 206–214
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC and Blum RH (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 14: 7–17
Kushner BH and Cheung NKV (1989) GM-CSF enhances 3F8 monoclonal antibody-dependent cellular toxicity against human melanoma and neuroblastoma. Blood 73: 1936–1941
Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C and Papadopoulos N (1998) Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16: 1752–1759
Leong SP, Enders-Zohr P, Zhou YM, Stuntebeck S, Habib FA, Allen RE, Sagebiel RW, Glassberg AB, Lowenberg DW and Hayes FA (1999) Recombinant human granulocyte macrophage colony stimulating factor (rh GM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother 22: 166–174
Mazumder A, Agah R and Charak B (1990) Novel use of GMCSF as an antitumour immune potentiator after transplantation. Blood 76, (Suppl 1): abstr 2200
McNeel DG, Schiffman K and Disis ML (1999) Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor. Blood 93: 2653–2659
Metcalf D (1985) The granulocyte-macrophage stimulating factors. Science 229: 16–22
Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214
Nagler A, Shur L, Or R, Barak V, Condiotti R and Fabian I (1994) Granulocyte-macrophage colony-stimulating factor (GM-CSF) dependant monocyte-mediated cytotoxicity post-autologous bone marrow transplantation. Exp Hematol 22: 780abst 385
Rabinovich GA, Riera CM and Iribarren P (1999) Granulocyte-macrophage colony-stimulating factor protects dendritic cells from liposome-encapsulated dichloromethylene diphosphonate-induced apoptosis through a Bcl-2-mediated pathway. Eur J Immunol 29: 563–570
Ragnhammar P, Fagerberg J, Frodin JE, Hjelm AL, Lindemalm C, Magnusson I, Masucci G and Mellstedt H (1993) Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma. Long lasting complete remissions can be induced. Int J Cancer 53: 751–758
Ravaud A, Chevreau C, Cany L, Houyau P, Dohollou N, Roche H, Soubeyran P, Bonichon F, Mihura J, Eghbali H, Tabah I and Bui BN (1998) Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. J Clin Oncol 16: 2930–2936
Richard C, Alsar MJ, Calavia J, Bello-Fernandez C, Baro J, Loyola I, Rios R, Cuadrado MA, Gonzalez-Pardo C, Iriondo A, Conde E and Zubizzarreta A (1993) Recombinant human GM-CSF enhances T cell mediated cytotoxic function after ABMT for hematological malignancies. Bone Marrow Transplant 11: 473–478
Santoli D, Clark SC, Kreider BL, Maslin PA and Rovera G (1988) Amplification of IL-2 driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor. J Immunol 141: 519–526
Si Z, Hersey T and Coates AS (1996) Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 6: 247–255
Sieff CA (1987) Hematopoietic growth factors. J Clin Invest 79: 1549–1557
Spitler LE, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA and Soong SJ (2000) Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 18: 1614–1621
Steward WP, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D, Rouëssé J, Tursz T and Tueni E et al (1993) Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 11: 15–21
Szabolcs P, Moore MA and Young JW (1995) Expansion of immunostimulatory dendritic cells among myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. J Immunol 154: 5851–5861
American Society of Clinical Oncology (1996) Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 14: 1957–1960
Williams MA, Kelsey SM, Collins PW, Gutteridge CN, Bernard T and Newland AC (1994) Ex vivo augmentation of monocyte activation and antitumor potential of GM-CSF (Molgrastim) following intensive chemotherapy. Br J Hematol 86, (Suppl 1):20(abstr 72)
Willman CL, Stewart CC, Miller V, Yi TL and Tomasi TB (1989) Regulation of MHC class II gene expression in macrophages by hematopoietic colony-stimulating factors (CSF). Induction by granulocyte/macrophage CSF and inhibition by CSF-1. J Exp Med 170: 1559–1567
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ravaud, A., Delaunay, M., Chevreau, C. et al. Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial. Br J Cancer 85, 1467–1471 (2001). https://doi.org/10.1054/bjoc.2001.2120
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2120